THE USE OF L-ARGININE AS A NO DONOR IN OBSTETRIC PRACTICE
https://doi.org/10.36074/22.12.2019.v1.39
PDF (English)

Посилання

Gurevich, M.A. & Sturov, N.V. (2006). Nitric oxide deficiency and maintenance of vascular homeostasis: role of mononitrates and cytoprotection problems. The Difficult Patient, 3: 23–29.

Yelsky, V.N. & Vatutin, N.T. & Kalinkina, N.V. & Salakhova, A.M. (2008). The role of endothelial dysfunction in the genesis of cardiovascular disease. Journal. Academy of Medical Sciences of Ukraine, 14 (1): 51-62.

Ashurova NG, Ismatova MI. (2015). A modern look at the problem of fetal fetal developmental delay (Review article). Science. Thought, 3, 13–18.

Facchinetti, F. & Saade, G.R. & Neri, I. et al. (2007). L-arginine supplementation in patients with gestational hypertension: a pilot study. Hypertens Pregnancy, 26 (1): 121-130.

Rytlewski, K. & Olszanecki, R. & Korbut, R. & Zdebski, Z. (2005). Effects of prolonged oral supplementation with l -arginine on blood pressure and nitric oxide synthesis in preeclampsia. Eur. J. Clin. Invest., 35 (1): 32-37.

Rytlewski, K.& Olszanecki, R. & Lauterbach, R. et al. (2006). Effects of oral L-arginine on the foal condition and neonatal outcome in preeclampsia: a preliminary report. Basic Clin. Pharmacol. Toxicol., 99 (2): 146–152.

Sieroszewski, P. & Suzin J. & Karowicz-Bilińska, A. (2004). Ultrasound evaluation of intrauterine growth restriction therapy by a nitric oxide donor (L-arginine). J. Matern. Fetal Neonatal Med., 15 (6): 363–366.

Zhang, N. & Xiong, A.H.& Xiao, X.& Li, L.P. (2007). Effect and mechanism of L-arginine therapy for fetal growth retardation due to pregnancy-induced hypertension. Nan. Fang Yi Ke Da Xue Xue Bao, 27 (2): 198–200.

Creative Commons License

Ця робота ліцензується відповідно до Creative Commons Attribution 4.0 International License.

Завантаження

Дані завантаження ще не доступні.

| Переглядів: 9 | Завантажень: 10 |